Piper Jaffray Downgrades Anthera Pharma (ANTH) to Underweight; PT $0.10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura
March 12, 2018 8:00 AM EDTSollpura did not achieve the primary endpoint of the coefficient of fat absorption (CFA)Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption (CNA)Further development of Sollpura to be discontinuedAnthera to evaluate all strategic alternativesAnthera to host teleconference today at 8:30 am ET
HAYWARD, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:... More
